---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-265717"
form_type: "8-K"
ticker: "VRDN"
cik: "0001590750"
company_name: "Viridian Therapeutics, Inc.\\DE"
filed_at: "2023-10-30T23:59:59+00:00"
generated_at: "2026-06-09T06:00:03.832992+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Viridian Therapeutics announces new CEO, $185M private placement, next-gen FcRn inhibitors

## Summary
- Stephen Mahoney appointed President and CEO, succeeds Scott Myers. Base salary $650k, 55% bonus target, option for 1.26M shares.
- $185M private placement: 8.79M shares at $12.38, plus 92,312 convertible preferred shares. Closing expected Nov 1, 2023.
- Discloses preclinical FcRn inhibitors VRDN-006 and VRDN-008; first IND filing by year-end 2024. Targets autoimmune diseases.
- TED pipeline: subcutaneous program selection by end 2023; VRDN-001 THRIVE Phase 3 active TED readout mid-2024.
- Thomas Beetham appointed COO; base salary $500k, 45% bonus target, option for 474k shares.

## SEC filing metadata
- accession: 0001193125-23-265717
- form_type: 8-K
- ticker: VRDN
- cik: 0001590750
- company_name: Viridian Therapeutics, Inc.\DE
- filed_at: 2023-10-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 3.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590750/000119312523265717/0001193125-23-265717-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590750/000119312523265717/d567471d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-265717
- JSON: https://secwatch.observer/filing/0001193125-23-265717.json
- Plain text: https://secwatch.observer/filing/0001193125-23-265717.txt

## Key facts
- Executive change
  Stephen Mahoney was appointed as Director at Viridian Therapeutics, Inc.\DE.
  - Action: appointed
  - Role: Director
  source text: Mr. Mahoney was also appointed to the Company’s Board of Directors (the “Board”) as a Class III Director to serve until the Company’s 2024 Annual Meeting of Stockholders and until his successor is duly elected and qualified.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590750/000119312523265717/0001193125-23-265717-index.htm
- Executive change
  Stephen Mahoney was appointed as President and Chief Executive Officer at Viridian Therapeutics, Inc.\DE.
  - Action: appointed
  - Role: President and Chief Executive Officer
  source text: On October 30, 2023, the Company announced the appointment of Stephen Mahoney as the Company’s President and Chief Executive Officer, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590750/000119312523265717/0001193125-23-265717-index.htm
- Material Agreements
  Viridian Therapeutics, Inc.\DE entered into Securities Purchase Agreement with certain institutional and accredited investors valued at approximately $185 million (effective 2023-10-30).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional and accredited investors
  - Value: approximately $185 million
  - Effective: 2023-10-30
  source text: On October 30, 2023, Viridian Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) for a private placement (the “Private Placement”) with certain institutional and accredited investors (each, a “Purchaser” and collectively, the “Purchasers”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590750/000119312523265717/0001193125-23-265717-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.